INNIDE THIS ISSUE

- Benefit Drug List – l-Asparaginase (PEG Asparaginase)
- New Lymphoma Treatment Guidelines
- Protocol Update – BRAVTRAP, UBRAVTR, GOEP, GOOVCARB, LYACOP6, LYACOP12, LYCLUDOR, LYCHOP, Lycopa, Lycyclo, Lycdmox, Lydmoxr, Lyice, Oshdmox
- Pre-Printed Order Update – GIENDO2, GOCXRADC, HNFUA, LYECV
- Patient Education – Temozolomide, Trastuzumab, Warfarin
- Drug Update – Switch from Streptokinase to Alteplase (r-tPA) to clear Occluded Central Venous Catheters
- Cancer Drug Manual – Revision for the 3rd edition
- Nursing Practice Tips – Care of Central Venous Catheters, Double-Checking of Ambulatory Chemotherapy Infusion Pumps, Care of Malignant Wound and Radiation Skin Reaction
- Library/Cancer Information Centre – Unconventional Cancer Therapies Manual
- Continuing Education – Partnerships in Cancer Care 2000, BCCA Annual Clinical Cancer Conference

FAX request form and IN TOUCH phone list are provided if additional information is needed.

BENEFIT DRUG LIST

The following new program has been funded by the Provincial Systemic Therapy Program effective:

- L-asparaginase (PEG asparaginase, pegasparagase) for pediatric patients with acute lymphoblastic leukemia treated on the COG-1991 study

This drug is now approved as a Class II drug on the benefit list. A Class II form must be completed and submitted to the Provincial Systemic Therapy Program before the drug will be dispensed at a regional cancer centre or reimbursed to a community hospital.

Susan O’Reilly, MB, FRCPC
Provincial Systemic Program Leader

NEW LYMPHOMA TREATMENT GUIDELINES

Recently the BCCA Lymphoma Tumor Group reviewed the results of its treatment policies for diffuse large B-cell lymphoma (DLBC) for the past 20 years. This extensive review showed that the current protocols (LYACOP6, LYACOP12, Lycopa) appear to be as effective as but offer no sufficiently compelling advantages over the international standard, CHOP, to justify their continuing use instead of CHOP. On the other hand, the ability to cooperate in international and national research efforts will be definitely enhanced by shifting to the CHOP regimen.

For these and other reasons including cost savings, the Lymphoma Tumor Group has decided to make the following changes as of 1 August 2000 for patients with DLBC:

<table>
<thead>
<tr>
<th>Patient group</th>
<th>Current protocol</th>
<th>New protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage IA or IIA, low bulk</td>
<td>LYACOP6 + RT</td>
<td>LYCHOP x 3 cycles + RT</td>
</tr>
<tr>
<td>Stage III or IV, or B symptoms or bulky disease, age &lt; 70</td>
<td>LYACOP12</td>
<td>LYCHOP x 6-8 cycles</td>
</tr>
<tr>
<td>Stage III or IV, or B symptoms or bulky disease, age ≥ 70</td>
<td>Lycopa</td>
<td>LYCHOP x 6-8 cycles</td>
</tr>
<tr>
<td>Advanced stage + adverse prognostic factors</td>
<td>LYACOP + LYECV</td>
<td>LYCHOP x 6-8 cycles</td>
</tr>
<tr>
<td>Relapsed disease with plan for high dose chemo + stem cell transplant</td>
<td>Cyclophosphamid</td>
<td>LYICE</td>
</tr>
</tbody>
</table>

Joe Connors, MD
Chair, BCCA Lymphoma Tumour Group
**PROTOCOL UPDATE**

Protocol codes for treatments requiring “Undesignated Indication” approval prior to use are prefixed with the letter U.

- INDEX to BCCA Protocol Summaries
  revised monthly (includes tumour group, protocol code, indication, drugs, last revision date and version)

- BRAVTRAP revised (warfarin interaction added) Therapy for metastatic breast cancer using trastuzumab and paclitaxel

- UBRAVTR revised (warfarin interaction added) Therapy for metastatic breast cancer using trastuzumab

- GOEP revised (typo corrected under Tests): Therapy of dysgerminomatous ovarian germ cell cancer using cisplatin and etoposide

- GOOVCARB revised (typo corrected under Tests): First or second line therapy for invasive epithelial ovarian cancer using single-agent carboplatin

- LYACOP6 deleted (replaced by LYCHOP for new patients): Treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone for 6 weeks. If a patient has already been started on LYACOP6, LYACOP12 or LYCOPA, it will be at the doctor's discretion as to whether or not to switch to CHOP or complete the current treatment.

- LYACOP12 deleted (replaced by LYCHOP for new patients): Treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone. If a patient has already been started on LYACOP6, LYACOP12 or LYCOPA, it will be at the doctor's discretion as to whether or not to switch to LYCHOP or complete the current treatment.

- LYCHLOR reformatted: Therapy for low grade lymphoma and chronic lymphocytic leukemia using chlorambucil

- LYCHOP new (replacing LYACOP6, LYACOP12, and LYCOPA): Treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP).

- LYCOPA deleted (replaced by LYCHOP for new patients): Treatment of lymphoma with doxorubicin, vincristine and cyclophosphamide. If a patient has already been started on LYACOP6, LYACOP12 or LYCOPA, it will be at the doctor's discretion as to whether or not to switch to CHOP or complete the current treatment.

- LYCYCLO reformatted: Therapy of lymphoma, Hodgkin’s disease, chronic lymphocytic leukemia or multiple myeloma using cyclophosphamide

- LYHDMTX deleted (replaced by LYHDMTXP and LYHDMTXR): Treatment of leptomeningeal lymphoma or recurrent intracerebral lymphoma with high dose methotrexate

- LYHDMTXP new (replacing LYHDMTX): Treatment of primary intracerebral lymphoma with high dose methotrexate

- LYHDMTXR new (replacing LYHDMTX): Treatment of leptomeningeal lymphoma or recurrent intracerebral lymphoma with high dose methotrexate

- LYICE new: Treatment of lymphoma with ifosfamide, carboplatin and etoposide

- OSHDMTX revised (Bleyer diagram added): Treatment of osteosarcoma using high dose methotrexate with leucovorin rescue

**PRE-PRINTED ORDER UPDATE**

Pre-printed orders should always be checked with the most current BCCA protocol summaries. The Vancouver Cancer Centre has prepared the following chemotherapy pre-printed orders, which can used as a guide for reference:

- GIENDO2 new: Palliative therapy for pancreatic endocrine tumours using streptozocin and doxorubicin

- GOCXRADC revised (pre-printed orders titled GOCXRADC Pretreatment and GOCXRADC): Treatment of high risk squamous cell carcinoma of cervix with concurrent cisplatin and radiation

- HNFUA new: Therapy for initial treatment for advanced head and neck cancer using split course radiation therapy combined with mitomycin C and fluorouracil

- LYECV new: Etoposide and cyclophosphamide consolidation for lymphoma

An index to the orders can be obtained by Fax-back.
**PATIENT EDUCATION**

**Temozolomide handout** is now available. This is a new benefit drug used for recurrent malignant gliomas.

**Trastuzumab (Herceptin®) handout** has been revised to include interaction with warfarin (see below). Guidelines regarding additional monitoring of warfarin have also been added to the BCCA protocols for trastuzumab (see BRAVTRAP and UBRAVTR in Protocol Update).

**Warfarin handout** has been revised to include two new drug interactions: St John’s Wort and trastuzumab (Herceptin®). St. John’s Wort is an herbal product commonly used for depression, while trastuzumab is a monoclonal antibody used in breast cancer. Guidelines regarding additional monitoring of warfarin have also been added to the BCCA protocols for trastuzumab (see BRAVTRAP and UBRAVTR in Protocol Update).

**DRUG UPDATE**

**Alteplase (r-tPA) and Streptokinase for Occluded Central Venous Catheters**

Alteplase (r-tPA) is now the standard fibrinolytic agent for clearing occluded catheters at the BCCA regional cancer centres. This change will be in line with the practice in many Canadian tertiary care centres, Vancouver Hospital and Health Sciences Centre, and BCCA host hospitals. Literature evidence for the use of alteplase for this indication exists. Other fibrinolytic agents, such as urokinase and streptokinase, have also been used to clear occluded venous catheters. However, urokinase became unavailable due to potential viral contamination, while streptokinase carries a very small risk of hypersensitivity reactions and anaphylaxis with repeated exposure.

Pre-filled syringes containing 1mg/mL alteplase solution are manufactured in bulk, frozen, and stored -20°C for up to 6 months. This aliquoting and freezing of alteplase syringes is necessary if alteplase is to be cost-effective. The recommended dosing and administration are:

- use 2 mg/2 mL solution to fill internal volume of occluded catheter + 0.2 mL (e.g., if lumen volume is 1.2mL, instil 1.4mL into lumen)
- Instil x 1 hour; may repeat x 1. (extra 0.2 mL to ensure alteplase reaches catheter tip where a fibrin sheath may exist)
- for calculated volumes greater than 2 mL, fill syringe to appropriate volume with normal saline

New Pharmacy and Nursing procedures on the logistics of preparation, freezing and using alteplase before its expiry will be implemented at the BCCA Cancer Centres in August 2000.

Suzanne Taylor, BScPharm, PharmD, BCPS
BCCA Pharmacoeconomics/Clinical Pharmacist

**CANCER DRUG MANUAL**

**Cancer Drug Manual Revision** The Cancer Drug Manual is currently being revised for the 3rd edition. It is anticipated that over 20 new cancer drugs will be included in the new edition. We would appreciate your comments on how to improve on the contents and formats of the Cancer Drug Manual.

For more information on the Cancer Drug Manual revision, contact Mário de Lemos, Editor, Cancer Drug Manual, at tel: (604) 877-6098 ext 2288, fax: (604) 708-2024, or e-mail: mdelemos@bccancer.bc.ca.

**NURSING PRACTICE TIPS**

The BCCA Nursing has changed the following policies. Request for further information on any of these changes can be made to the Regional Professional Practice Leader of Nursing at the BCCA Cancer Centre within your region.

1. **Care of Central Venous Catheters** A review of the literature has resulted in the following changes to the policies that guide the care and maintenance of all central lines:

   - PICC Insertion – implementation of a two-step method of insertion
   - PICC Care – updated “trouble-shooting guide for nurses” which provides more direction in the management of phlebitis and skin irritation
• Use of only 10 mL or larger syringes for IV push medications
• Dressings – use of semi-occlusive dressings
• Unblocking catheters – use of alteplase (tPA) instead of streptokinase

2. Double-Checking of Ambulatory Chemotherapy Infusion Pumps
To increase the safety of patients going home with mechanical infusion pumps containing chemotherapy agents, two chemotherapy-certified registered nurses should double check the programming of the pumps and sign that the check has been done.

3. Care of Malignant Wound and Radiation Skin Reaction
The practice guidelines in both of these areas are currently under revision and near completion.

Linda Yearwood, MSN
BCCA Regional Professional Practice Nursing Leader

LIBRARY/CANCER INFORMATION CENTRE
Unconventional Cancer Therapies Manual
The new 3rd edition (2000) of the Unconventional Cancer Therapies Manual for patients is now available for purchase for $35 from the BCCA Library/Cancer Information Centre (see phone listing at the end of the Update), or may be consulted at BCCA website: http://www.bccancer.bc.ca/uct/

The manual consists of 46 short monographs on the more popular alternative cancer therapies, and includes tips for the patient and family on how alternative therapies can be evaluated. For each therapy (e.g., Essiac, vitamins, teas, shark cartilage, etc.), the manual provides proponent/advocate claims, balanced by evidence-based professional evaluation/critique quotations from the literature.

Photocopying from the manual's binder-formatted print version, or downloading monographs as needed from the BCCA website, is encouraged for cancer patients and families.

David Noble, BSc, BSL
BCCA Library/Cancer Information Centre Leader

CONTINUING EDUCATION
Partnerships in Cancer Care 2000 will take place on Thursday, 23 November, 2000 at the Sheraton Wall Centre in Vancouver. This year’s theme will be “Strategic Planning for Community Cancer Services-the Long Term View”. Agency and community breakout groups will participate in strategic planning for the provincial cancer services. Information Technology, Human Resource Planning, Professional Education/Training and Who does What, Where? will be the focus group topics. Participants will be invited from twenty BCCA Community Cancer Centres.

The Partnership meeting will be coupled to the BCCA Annual Clinical Cancer Conference Friday and Saturday the 24 and 25 November. Friday morning will feature separate sessions for the provincial oncology nurses, pharmacists and physician oncologists. Friday afternoon and all day Saturday is devoted to breast, prostate and diagnostic services tumour group presentations. Theatre Sports will entertain at the Friday night banquet.

ERRATUM
Protocol Update July 2000 The new protocol for the primary treatment of advanced/recurrent non-small cell cancer of the cervix with carboplatin and paclitaxel in ambulatory care settings should have been UGOCXCAT, and not UGOOVCXCAT.

Editorial Review Board
Mário de Lemos, PharmD (Editor)
Sharon Allan, MD
Sandi Broughton, BA(Econ), MSc
Jack Chritchley, MD
Linda Yearwood, MSN
Lynne Nakashima, PharmD
David Noble, BSc, BLS
Lynn Stevenson, RN
Kelly Uyeno, CGA
Gigi Concon (Secretary)
### Bulletin Updates

<table>
<thead>
<tr>
<th>Bulletin Updates</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Handouts:</td>
<td>H:\everyone\systemic\chemo\Pt_Educ</td>
</tr>
<tr>
<td>Temozolomide</td>
<td></td>
</tr>
<tr>
<td>Trastuzumab</td>
<td></td>
</tr>
<tr>
<td>Warfarin</td>
<td></td>
</tr>
<tr>
<td>Pre-Printed Orders</td>
<td>H:\everyone\systemic\chemo\Orders\VCC</td>
</tr>
<tr>
<td>Index of Pre-Printed Orders</td>
<td>H:\everyone\systemic\chemo\Orders\VCC\Index.doc</td>
</tr>
<tr>
<td>G1ENDO2</td>
<td></td>
</tr>
<tr>
<td>GOCXRADC</td>
<td></td>
</tr>
<tr>
<td>HNFUA</td>
<td></td>
</tr>
<tr>
<td>LYEVC</td>
<td></td>
</tr>
<tr>
<td>Protocol Summaries</td>
<td>H:\everyone\systemic\chemo\Protocol&quot;tumour site&quot;</td>
</tr>
<tr>
<td>BRAVTRAP</td>
<td></td>
</tr>
<tr>
<td>UBRAVTR</td>
<td></td>
</tr>
<tr>
<td>GOEP</td>
<td></td>
</tr>
<tr>
<td>GOOVCARB</td>
<td></td>
</tr>
<tr>
<td>LYCHLR</td>
<td></td>
</tr>
<tr>
<td>LYCHOP</td>
<td></td>
</tr>
<tr>
<td>LYCYCLO</td>
<td></td>
</tr>
<tr>
<td>LYHDMTXP</td>
<td></td>
</tr>
<tr>
<td>LYHDMTXR</td>
<td></td>
</tr>
<tr>
<td>LYICE</td>
<td></td>
</tr>
<tr>
<td>OSHDMTX</td>
<td></td>
</tr>
<tr>
<td>Index of Protocol Summaries</td>
<td>H:\everyone\systemic\chemo\Protocol\Index\Index_NT or Index_W6</td>
</tr>
<tr>
<td>Reimbursement</td>
<td>H:\everyone\systemic\chemo\Reimburs</td>
</tr>
<tr>
<td>Benefit Drug List</td>
<td>BenefitList.doc</td>
</tr>
<tr>
<td>Class 2 Form</td>
<td>Class2.doc</td>
</tr>
</tbody>
</table>

For easy access, double-click your systemic chemo icon.
We appreciate your comments. Write us at bulletin@bccancer.bc.ca
BCCA SYSTEMIC THERAPY UPDATE FAX REQUEST FORM

FAX (604) 877-0585
bulletin@bccancer.bc.ca

TO SUBSCRIBE: FAX OR EMAIL YOUR REQUEST OR CALL @ 877-6098 LOCAL 2247
FOR URGENT REQUESTS PLEASE CALL (604) 877-6098 LOCAL 2247
OR TOLL-FREE IN BC 1-800-663-3333 LOCAL 2247

PLEASE FEEL FREE TO MAKE COPIES FOR YOUR COLLEAGUES

I WOULD PREFER TO RECEIVE THIS INFORMATION VIA:

| ☐ | E-mail (Word 6.0) | @ |
| ☐ | Fax | ( ) | Attn: |

UPDATES  Please ☑ Fax-Back information below:

- ☐ All items
- ☐ Patient Handouts:
  - ☐ Temozolomide
  - ☐ Trastuzumab
  - ☐ Warfarin
- ☐ Pre-Printed Orders:
  - ☐ GIENDO2
  - ☐ GOCXRADC
  - ☐ HNFUA
  - ☐ LYECV
  - ☐ Index: Pre-Printed Orders
- ☐ Protocol Summaries:
  - ☐ BRAVTRAP
  - ☐ UBRAVTR
  - ☐ GOEP
  - ☐ GOOVCARB
  - ☐ LYCHLOR
  - ☐ LYCHOP
  - ☐ LYCYCLO
  - ☐ LYHDMTXP
  - ☐ LYHDMTXR
  - ☐ LYICE
  - ☐ OSHDMTX
  - ☐ Index: Protocol Summaries (current month)

Reimbursement

- ☐ Benefit Drug List (1 August 2000)
- ☐ Class 2 Form (1 August 2000)

Systemic Therapy Update Index

- ☐ Jan-Jun 2000